S. Schold

Publications158
h-index53
Citations12,865
Highly Influential Citations275
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • D. Bigner
  • 811 Publications, 67,445 Citations
  • H. Friedman
  • 798 Publications, 43,477 Citations
  • J. Posner
  • 352 Publications, 26,987 Citations
  • A. Pegg
  • 687 Publications, 35,582 Citations
  • Publications
  • Influence
Response criteria for phase II studies of supratentorial malignant glioma.
We suggest "new" response criteria for phase II studies of supratentorial malignant glioma and favor rigorous criteria similar to those in medical oncology, with important modifications. Four… Expand
  • 2,215
  • 64
  • PDF
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
Chemotherapy for brain tumours has been limited because of difficulty in achieving adequate exposure to the tumour without systemic toxicity. We have developed a method for local sustained release of… Expand
  • 1,155
  • 24
Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.
PURPOSE Primary CNS lymphoma (PCNSL) is an aggressive primary brain tumor. Cranial irradiation alone rarely results in long-term disease control or prolonged survival. We prospectively studied the… Expand
  • 578
  • 19
Anti‐Ri: An antibody associated with paraneoplastic opsoclonus and breast cancer
The serum and cerebrospinal fluid (CSF) of 8 women with ataxia, 6 of whom also had eye movement abnormalities believed to be opsoclonus, were found to contain a highly specific antineuronal antibody… Expand
  • 354
  • 13
Increasing incidence of primary brain lymphoma in the US
There have been a number of clinical reports suggesting an increasing incidence of primary brain lymphoma unrelated to acquired immune deficiency syndrome (AIDS) and organ transplantation. To… Expand
  • 381
  • 10
Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas.
Malignant gliomas have been difficult to treat with chemotherapy. The most effective agent, BCNU (carmustine), has considerable systemic toxicity and a short half-life in serum. To obviate these… Expand
  • 420
  • 8
  • PDF
High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine.
BACKGROUND P-glycoprotein mediates resistance to natural-product anti-neoplastic agents like vinblastine through an active transport process resulting in reduced intracellular concentration of these… Expand
  • 206
  • 8
Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.
PURPOSE Prior studies show that increased levels of the DNA repair protein O6 methylguanine-DNA methyltransferase (MGMT), also referred to as O6-alkylguanine-DNA alkyltransferase (AGT) correlate with… Expand
  • 307
  • 7
Multifaceted resistance of gliomas to temozolomide.
PURPOSE AND EXPERIMENTAL DESIGN The contributions of O6-methylguanine-DNA-methyltransferase(MGMT), p53 status, mismatch repair, and apoptotic response to the resistance of glial tumors to… Expand
  • 108
  • 6
  • PDF
Fibronectin and glial fibrillary acidic protein expression in normal human brain and anaplastic human gliomas.
Abstract The expression of fibronectin (FN), an extracellular matrix glycoprotein with adhesive and opsonic properties, was examined in normal and neoplastic human central nervous system tissues. In… Expand
  • 97
  • 6
  • PDF